tirzepatide 50 mg vial Lilly launches lower-price weight-loss drug without injector pen Most Successful Weight Loss Program. Eli Lilly Launches Self-Pay Vials

With advantages like dual action targeting both GLP-1 and GIP receptors, improved glycemic control, enhanced overall metabolic benefits, high patient compliance, and superb quality formulation, our Tirzepatide Injection surpasses expectations to deliver noticeable health outcomes

Human Drug Compounding

As the national conversation around GLP-1 therapy continues to evolve, Ivim remains focused on data-driven outcomes and delivering care that adapts to each patient's unique needs

While extremely rare, a case of rhabdomyolysis associated with tirzepatide use was published in a peer-reviewed journal

Tirzepatide dramatically improves insulin sensitivity, often moving HbA1c from diabetic ranges to near-normal within months